Author(s): SM Rudresh, T Nagarathnamma
Extended spectrum β-lactamases (ESBLs) are plasmid mediated enzymes inactivating β-lactam antibiotics containing oxyimino group such as oxyimino-cephalosporins and oxyimino-monobactam, except cephamycins and carbapenems1. They are derived from the point mutation of plasmid determined TEM or SHV β-lactamases1,2. ESBLs are inhibited by clavulanic acid and placed under Bush’s functional class 2be3. Till date more than 200 different types of ESBLs have been described. In recent years, there is a dramatic increase in the prevalence of CTX-M type of ESBLs among clinical isolates of Enterobacteriaceae in Europe and Asia.